Hong Kong, July 17, 2009 - (ACN Newswire) - Lijun International Pharmaceutical (Holding) Co., Ltd. ("Lijun International" or the "Company"; stock code: 2005) and its subsidiaries (the "Group") are pleased to announce that the Group's unaudited profit attributable to the shareholders for the six months ended 30 June 2009 (the "Period") is expected to be close to the Group's audited profit attributable to the shareholders of approximately HK$102,106,000 for the year ended 31 December 2008.
Mr. Wu Qin, Chairman of Lijun International said: "Despite the global economic fluctuations in the first half of 2009, we recorded a profit growth during the Period, as we took advantage of the State's medical system reform, the growth in the size of domestic pharmaceutical market and the industry recovery, meanwhile, as market integration and business environment continued to improve, we are able to increase sales volume at relatively stable selling prices and achieve an increase in gross profit margin."
Mr. Wu added that: "Looking into the second half of the year, the Group is to continue to consolidate its leading role of macrolides antibiotics, strengthen intravenous infusion segment, boost the sales of general medicines and privileged brands, speed up the launches and enhance the sales of OTC and healthcare products. The Group will leverage on every chance to strengthen our development by focusing on the response to the new medical reform, keeping our eye on any possible market terminal changes brought by the implementation of the basic medicines system and the new medical reform, consolidating various characteristics of the Group's product as well as adjusting the strategies for both product development and marketing in time."
About Lijun International Pharmaceutical
As one of the leading manufacturers in the pharmaceutical industry in China, Lijun International Pharmaceutical (Holding) Co., Ltd. has more than 70-year operating history and well-known brands. The Group was listed on Hong Kong Stock Exchange in December 2005 (stock code: 2005). The Group is engaged in the research, development, manufacturing and selling of a wide range of finished medicines and bulk pharmaceutical products to hospitals and distributors, including antibiotics, intravenous infusion solution, non-antibiotics finished products, bulk pharmaceuticals and health care product. The Group has manufacturing plants in Hebei Province and Shaanxi Province, the People's Republic of China and sells to customers mainly in Mainland China. The Company is the largest domestic manufacturer of macrolide antibiotics, with a leading position for its intravenous infusion solution products in high-end hospital market. The Company boasts of its robust brand strength including "Lijuns
Contact:
Wonderful Sky Financial Group Limited
Joanne Chan / Miranda Fok / Daisy Sun
Tel: +852 2851 1038
Fax: +852 2815 1352
E-mail: joannechan@wsfg.hk / mirandafok@wsfg.hk / daisysun@wsfg.hk
July 17, 2009
Source: Lijun International Pharmaceutical
Lijun International Pharmaceutical
From the Japan Corporate News Network
http://www.japancorp.net
Topic: Press release summary
View more news from these Sectors: Chemicals
|
Print
Alerts
